MK-1084-004/​KANDLELIT-004

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.

• Studientyp: doppelblinde, randomisierte, multizentrische Studie
• Tumorart: Lungenkrebs
• Entität: NSCLC
• Standort:
  • Marienhospital
  • E-Mail: studienzentrum@vinzenz.de
  • Tel.: 0711 6489-8107
  • Website
• Rekrutierungsstatus: rekrutierend
• Alter: 18+
• Studienphase: Phase3
• Weitere Informationen